The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

The FDA has approved Johnson & Johnson’s drug Imaavy for the treatment of generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder. The approval covers adults and pediatric patients ...

Learn more about this approval in Johnson & Johnson’s news release ... and potentially life-changing treatment option. “FDA’s approval of IMAAVY TM (nipocalimab-aahu) is an important step ...

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal in a late-stage study on ...

IMAAVY TM (nipocalimab-aahu) is a first-in-class FcRn (neonatal Fc receptor) inhibitor, designed to reduce the levels of ...